-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US45175G2075 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 16 |
|---|---|
| PE Ratio | None |
| Market Cap | 67M |
| Beta | nan |
| Dividend Yield | None |
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IMA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026